Upjohn
This article was originally published in The Tan Sheet
Executive Summary
Receives supplemental NDA approval from FDA on July 29 to market Motrin IB Sinus (ibuprofen 200 mg/pseudoephedrine 30 mg). The company has been preparing for a launch during the upcoming cough/cough season ("The Tan Sheet" July 5, p. 19).